新型冠狀病毒

WHO approves emergency use of China’s Sinopharm vaccine

Authorisation allows jab to be deployed by Covax in boost for Chinese pharma industry

The World Health Organization has added a Sinopharm vaccine to its list of approved Covid-19 jabs, boosting the credentials of the China-made dose amid doubts over its efficacy.

The emergency use listing for the shot, developed in partnership with the Beijing Institute of Biological Products, is for a two-dose regimen for all adults aged 18 and over, said Tedros Adhanom Ghebreyesus, the WHO’s director-general.

It is the first vaccine of any kind made in China to receive emergency use authorisation from the WHO. The approval is a signal to countries that the Sinopharm vaccine is safe to use and means that the jab will be added to the WHO’s vaccine procurement programme Covax.

您已閱讀26%(681字),剩餘74%(1982字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×